ProMIS Neurosciences Announces Update to Senior Management Team
22. Oktober 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Files Special Meeting Proxy Material
21. Oktober 2021 07:00 ET
|
ProMIS Neurosciences Inc.
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO...
ProMIS Neurosciences Announces Special Shareholder Meeting
07. Oktober 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development...
ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
15. September 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference
13. September 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors
01. September 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
25. August 2021 09:44 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and CAMBRIDGE, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (the...
ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M
18. August 2021 10:49 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a...
ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units
18. August 2021 07:10 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a...
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
17. August 2021 16:40 ET
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a...